Lipella Pharmaceuticals, Inc. · OTC:LIPO
Lipella Pharmaceuticals — Investor Presentation (March 2023)
27 slides from Lipella Pharmaceuticals's investor presentation, March 2023
Slide 1: A Clinical Stage Biotechnology Company Addressing Serious Diseases
A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com
Slide 2: Disclaimers
NASDAQ:LIPO Disclaimers The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, “Lipella” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any information
Slide 3: Mission
NASDAQ:LIPO Mission Lipella is committed to providing supportive care to cancer survivors. Our mission is to develop and commercialize treatments for serious diseases resulting from cancer treatments including radiation and chemotherapy. A Clinical Stage Biotechnology Company Addressing Serious Dise
Slide 4: Business Growth Strategy
NASDAQ:LIPO Business Why rare and orphan drugs? Growth • Lipella can be first to market by pursuing conditions for which there are no current FDA approved treatments. • Requires smaller and less costly drug trials with greater flexibility from the Strategy FDA. • Orphan drug market exclusivity limit
Slide 5: About / Market Data
NASDAQ:LIPO Market Data About SYMBOL NASDAQ: LIPO Lipella Pharmaceuticals is a clinical-stage biotechnology Price as of 02-07-2023 $3.01 company developing new drugs 52 Week Range $2.31 - $7.72 by reformulating active agents in existing generic drugs for Average Volume ~934K serious diseases charact
Slide 6: Overview of Opportunity
NASDAQ:LIPO Overview of Opportunity Drug Development Drug Delivery Lead product candidate, LP-10, a 505(b)(2) drug candidate for Proprietary drug delivery hemorrhagic cystitis. technology with potential applications in bladder, urethra, LP-10 granted FDA Orphan Drug Designation; potential candidate
Slide 7: Executive Summary
NASDAQ:LIPO Executive Summary Emerging, clinical-stage, proprietary 505(b)(2) opportunity Drug-Delivery Focused Biotech Impressive Revenue Potential Optimized for 505(b)(2) epithelial tissues $20,000 $1.2 billion annual revenue annual revenue Patented liposomal local drug delivery Lower systemic per
Slide 8: Cancer Survivorship and Potential Addressable Market
NASDAQ:LIPO Cancer Prostate Cancer Uterine Corpus Cancers Rectal & Other Pelvic Survivorship 700,0001 Pelvic Radiation Survivors 200,0001 Pelvic Radiation Survivors 300,0001 Pelvic Radiation Survivors and Potential 42,0002 12,0002 18,0002 Addressable Severe HC Survivors Severe HC Survivors Severe HC
Slide 9: Asset Pipeline
NASDAQ:LIPO Asset Pipeline A growing pipeline with strong patent protection Product Target Marketing Next Anticipated Preclinical Phase 1 Phase 2 Phase 3 Candidate Indication Approval Milestone Hemorrhagic Communication with LP-10 Cystitis FDA 2Q23 Oral Lichen IND submission LP-310 Planus 3Q23 Submi
Slide 10: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss
NASDAQ:LIPO Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy. Millions of patients are 20% of these patients An increasing US Years after receiving Hemorrhagic cystit
Slide 11: LP-10 for Hemorrhagic Cystitis
NASDAQ:LIPO LP-10 for Hemorrhagic Cystitis Liposomal tacrolimus treatment for hemorrhagic cystitis Potent vasoconstrictor; reduces capillary blood flow to the bladder lumen Sterile powder Potent anti-inflammatory; inhibits cytokine Easy to deliver cascade and reduces injury to the bladder tissue Low
Slide 12: LP-10: an Outstanding Drug Candidate
NASDAQ:LIPO LP-10: an Outstanding Drug Candidate Multiple reasons increase LP-10 probability of success • Well Known mechanism of Well known Potential action mechanism 505(b)(2) $1.2 billion of action pathway Ongoing revenue • Pre-clinical efficacy clinical evidence • 505(b)(2) pathway • Potential $
Slide 13: LP-10: Phase 2a Trial
NASDAQ:LIPO LP-10: Phase 2a Trial A Phase 2a clinical trial (NCT01393223): Top line results Next Steps • Multi-center, dose-escalation • All subjects tolerated LP-10 • Successful completion of first in study instillations with no serious man Phase 2a multicenter clinical adverse events (SAE) reporte
Slide 14: LP-310 for Oral Lichen Planus
NASDAQ:LIPO LP-310 for Oral Lichen Planus Oral Lichen Planus (OLP) is a chronic inflammatory, T-cell-mediated autoimmune oral mucosal disease • Painful and comes with the risk of complications including infections, scarring, stress and depression. • Has malignant potential. • Most currently availabl
Slide 15: Manufacturing Capabilities
NASDAQ:LIPO Manufacturing Capabilities • Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products. • LP-10 has been produced at high quantities in this facility for Lipella's clinical trials. • The facility is also used for de
Slide 16: Experienced Management Team
NASDAQ:LIPO Experienced Management Team Lipella is led by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Chief Executive Officer Chief Medical Officer • 23+ Years Experience • 30+ Years Experience • Co-founded Li
Slide 17: Key Takeaways
NASDAQ:LIPO Key Takeaways Lead product candidate LP-10 for hemorrhagic cystitis • Successfully completed Phase 2a clinical trial. • Pursuing 505(b)(2) regulatory pathway. • Granted FDA Orphan Drug Designation. • Potential candidate for multiple accelerated pathways Peak annual revenue estimates in h
Slide 18: A Clinical Stage Biotechnology Company Addressing Serious Diseases
A Clinical Stage Biotechnology Company Addressing Serious Diseases with NASDAQ:LIPO Significant Unmet Need Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 lipellapharmaceuticals.com
Slide 19: Appendix
NASDAQ:LIPO Appendix A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 19
Slide 20: LP-10 Phase 2a Trial Summary
NASDAQ:LIPO LP-10 Phase 2a Trial Summary Key inclusion criteria: Key Exclusion criteria: 1. Males and females, at least 18 years 1. Patients taking immunosuppressive therapy 2. History of sterile moderate to severe HC (Grades 2. History of interstitial cystitis/bladder pain 2-4) for at least 3 month
Slide 21: LP-10 Phase 2a Trial Summary
NASDAQ:LIPO LP-10 Phase 2a Trial Summary Multi-center, dose-ranging study Details Indication Refractory moderate-to-severe hemorrhagic cystitis (HC) Dose ranging study to evaluate safety, tolerability, and efficacy Protocol design of LP-10 Subjects 12 Male and Female subjects from 5 sites Treatment
Slide 22: LP-10 Phase 2a Trial Summary
NASDAQ:LIPO LP-10 Phase 2a Trial Summary Recruitment sites and subject disposition Patient Disposition Number Comments Screened, n 15 14 male, 1 female Enrolled, n 13 13 male 2 instillations (n=10) Number of instillations 23 1 instillation (n=3) Discontinued, % 0 Withdrew consent, % 0 Lack of compli
Slide 23: LP-10 Phase 2a Trial Summary
NASDAQ:LIPO LP-10 Phase 2a Age, years Mean 67 Comment Range 25-89 Trial Summary Race • White 9 • Non-White 4 Radiation induced HC 11 Patient Demographics Chemotherapy induced HC 2 Cancer • Prostate cancer 9 • Bladder cancer 2 • Lymphoma 2 Duration of HC years 4 Range 1 -14 years medication, HBO, cat
Slide 24: LP-10 Safety
NASDAQ:LIPO Number Comment LP-10 Safety Product related significant adverse events Subject discontinuations 0 0 Adverse events (AE) Number of subjects with adverse events 6/13 12 AEs reported in 6 subjects 2 mg: 4 AEs in 3 subjects 4 mg: 2 AEs in 1 subject 8 mg: 6 AEs in 2 subjects Bladder spasm, ur
Slide 25: LP-10 Pharmacokinetics and Safety
NASDAQ:LIPO LP-10 Pharmacokinetics and Safety Local delivery of tacrolimus limits systemic distribution • < 1.5 ng/ml considered Subject Group Baseline 1 hour 2 hours 4 hours 48 hours undetectable 1 2 mg - - 1.5 - - 2 2 mg - 2.3 - - - • All Levels were within the safe 3 2 mg - 3.0 1.7 - - range, < 1
Slide 26: LP-10 Responder Analysis
NASDAQ:LIPO LP-10 Responder Analysis Evaluating cystoscopy, hematuria, and symptoms (NR=“no response”, PR=“partial response”, cystoscopy CR=“complete response”) hematuria (normalized rank, 0 to 9) CR in all subjects symptoms normalized response rank 9 • Efficacy improvement reported 8 by principal i
Slide 27: Company History
NASDAQ:LIPO Company History Born out of an NIH funded research collaboration on liposomal drug delivery to become a clinical-stage pharmaceutical company with a growing pipeline. Submit LP-310 IND Jonathan Kaufman Michael Chancellor LP-10 FDA Orphan Platform patent Doug Johnston Completed Phase-2a S
Lipella Pharmaceuticals — Investor Presentation (March 2023) on 6ix